Holen Sie sich die Stockscreener-App
522.02
0.10%
0.52
Handel nachbörslich:
522.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$521.50
Offen:
$517.2
24-Stunden-Volumen:
354.75K
Relative Volume:
0.60
Marktkapitalisierung:
$41.13B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
38.41
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
+1.64%
1M Leistung:
-6.27%
6M Leistung:
-9.76%
1J Leistung:
-19.49%
1-Tages-Spanne:
$516.88
$523.22
1-Wochen-Bereich:
$501.98
$523.95
52-Wochen-Spanne:
$500.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
522.02 | 41.08B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
665.30 | 243.49B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
221.56 | 155.42B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
390.79 | 56.35B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
165.32 | 47.16B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
267.86 | 44.46B | 16.63B | 1.39B | 2.12B | 8.0674 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Singapore
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Should You Continue to Hold IDXX Stock in Your Portfolio? - TradingView
IDEXX Laboratories stock gains as revenue outlook meets premium valuation - AD HOC NEWS
IDEXX Laboratories stock heads into the open after a 1.16 percent gain - AD HOC NEWS
IDEXX Laboratories Acquires CoVetAI to Enhance Veterinary Software Ecosystem - Global Legal Chronicle
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock gains 1.16 percent as valuation holds - AD HOC NEWS
IDEXX Laboratories stock heads into the open after recent gains - AD HOC NEWS
IDEXX Laboratories stock gains after double digit Q2 growth and raised guidance - AD HOC NEWS
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof - DVM360
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets - Yahoo Finance
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference - Yahoo Finance
IDEXX Laboratories stock gains attention after CoVetAI deal and Stifel Buy rating - AD HOC NEWS
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics - Yahoo Finance
IDEXX Laboratories Inc | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
IDEXX Laboratories stock holds after Stifel keeps Buy rating - AD HOC NEWS
Why Is the Market Reassessing IDEXX Laboratories (IDXX)? - Kalkine Media
IDEXX Laboratories stock holds Stifel Buy rating after Q2 earnings beat - AD HOC NEWS
Stifel reiterates Buy on IDEXX Laboratories stock citing vet survey By Investing.com - Investing.com Australia
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide - Yahoo Finance
IDEXX Laboratories stock heads into the open after a modest pullback - AD HOC NEWS
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Vet Candy
IDEXX Laboratories stock gains as CoVetAI deal and new parasite tests bolster growth narrative - AD HOC NEWS
IDEXX Stock Gains Following the Acquisition of CoVet - TradingView
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection - PA Media
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $670 - Moomoo
IDEXX Laboratories (IDXX) Looks 19.8% Undervalued on GF Value™ - gurufocus.com
IDEXX Laboratories Acquires Veterinary AI Software Firm CoVetAI - marketscreener.com
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 38% Potential Upside For Investors - directorstalkinterviews.com
IDXX - Finviz
IDEXX Laboratories stock gains as analysts lift targets - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories stock reacts to insider share sale and recent earnings strength - ad-hoc-news.de
Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories - Benzinga
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock - The Motley Fool
Is IDEXX Laboratories Stock Underperforming the Dow? - inkl
Idexx Laboratories stock hits 52-week low at $517.00 By Investing.com - Investing.com Australia
IDEXX Laboratories (IDXX) director exercises options and sells 2,203 shares - Stock Titan
Idexx Laboratories stock hits 52-week low at $517.00 - Investing.com
IDEXX Laboratories stock heads into the open after a modest gain - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories stock holds near recent highs as diagnostics demand supports growth - ad-hoc-news.de
Down 16% in the Last 12 Months, Can IDEXX Stock Bounce Back in 2027? - TIKR.com
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 - GlobeNewswire Inc.
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring A 30% Upside Potential - DirectorsTalk Interviews
IDEXX Laboratories stock gains after strong Q2 results and raised 2026 outlook - ad-hoc-news.de
ETFs Investing in IDEXX Laboratories, Inc. Stocks - TradingView
IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
IDEXX Laboratories stock steadies after strong Q2 2026 results and raised outlook - AD HOC NEWS
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
3.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):